Q-omics provides the consensus-scored LINC01549 profile across patient tissues and cancer cell-line models. LINC01549 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01549 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, LINC01549 RNA expression shows 9,047 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LIHC, and TGCT as cancer lineages where LINC01549 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01549 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01549 survival associations across molecular data types. LINC01549 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01549 RNA expression–survival associations across cancer types. High LINC01549 expression shows unfavorable associations in KIRC, UCS, ACC, KICH and UVM, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01549 RNA expression.
This table summarizes LINC01549 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01549. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01549 shows lower tumor expression in HNSC and KICH and higher tumor expression in LIHC, COAD, LUAD and LUSC. The LIHC box plot shows higher LINC01549 RNA expression in tumor versus normal tissue (log2 FC = +0.803, t-test p < 0.001).
This table shows molecular features associated with LINC01549 in patient tissues and cancer cell lines. In patient samples, LINC01549 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01549 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS.
